Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
biotech
boston
clinical trials
national top stories
san diego blog main
dyne therapeutics
myotonic dystrophy type 1
new york blog main
rare disease drugs
san diego top stories
san francisco blog main
akcea therapeutics
ally bridge group
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
cardiomyopathy
casdin capital
diabetic nephropathy
drugs
duchenne muscular dystrophy
eli lilly
europe blog main
europe top stories
eventide asset management
What
drug
5
×
genetic
5
×
medicines
5
×
ipo
rare
ago
company
diseases
dyne
fda
million
muscle
raised
therapeutics
address
akcea
alnylam
amyloidosis
analysis
approval
approved
approves
attr
available
battle
bio
biotech
biotechs
blueprint
bring
brings
cancer
carries
certain
considering
data
debilitating
designed
develop
developing
Language
unset
Current search:
drug
×
medicines
×
genetic
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea